2-es típusú diabetes gondozása során felfedezett polymyositis-dermatomyositis

Translated title of the contribution: Polymyositis-dermatomyositis recognized during the follow-up of a patient with type 2 diabetes

Francis Samer, Mária Csóka, K. Dankó

Research output: Contribution to journalArticle

Abstract

Polymyositis-dermatomyositis is a rare systemic autoimmune disease which belongs to the class of idiopathic inflammatory myopathies. The disease exhibits high inter-individual variability, but chronic myositis is a common feature. As different manifestations often appear in atypical forms, establishing the precise diagnosis can be rather complicated. The prognosis and the patient's life expectations highly depend on whether the clinician considers this possibility in the diagnostic process or not. The authors present the case of a 50-year-old woman who was referred to hospital with suspected myopathy by her general practitioner. The history of the patient, the overall clinical picture and some marked laboratory abnormalities raised the possibility of polymyositis-dermatomyositis, which was unequivocally confirmed by immunological tests. Drug therapy was started immediately with the administration of high dose corticosteroid (1-2 mg/kg/day methylprednisolone), which was found to be an effective strategy leading to fast and remarkable improvement in the patient's condition. From the first hospital day, the patient also received insulin therapy in order to prevent any potential corticosteroid-induced imbalance in her carbohydrate metabolism. The long-term patient management was provided by an interdisciplinary team the members of which (both clinicians and other health care professionals) worked according to a co-ordinated, complex care plan, and managed not only the "physiological functions" but the different psychological and social problems as well, which are usually associated with the disease. The follow-up period of this polyphase disease process lasted for 4.5 years, during which only two relapses occurred, and muscle strength typically varied between 3 and 4 on a five grade scale with the exception of the relapse periods. Good outcome was attributed to the strict follow-up and individualized therapy/care.

Original languageHungarian
Pages (from-to)467-474
Number of pages8
JournalOrvosi Hetilap
Volume153
Issue number12
DOIs
Publication statusPublished - Mar 1 2012

Fingerprint

Dermatomyositis
Type 2 Diabetes Mellitus
Myositis
Adrenal Cortex Hormones
Recurrence
Immunologic Tests
Social Problems
Methylprednisolone
Carbohydrate Metabolism
Muscle Strength
Managed Care Programs
Muscular Diseases
General Practitioners
Autoimmune Diseases
History
Insulin
Psychology
Delivery of Health Care
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

2-es típusú diabetes gondozása során felfedezett polymyositis-dermatomyositis. / Samer, Francis; Csóka, Mária; Dankó, K.

In: Orvosi Hetilap, Vol. 153, No. 12, 01.03.2012, p. 467-474.

Research output: Contribution to journalArticle

Samer, Francis ; Csóka, Mária ; Dankó, K. / 2-es típusú diabetes gondozása során felfedezett polymyositis-dermatomyositis. In: Orvosi Hetilap. 2012 ; Vol. 153, No. 12. pp. 467-474.
@article{8ee348be42054148b95da32269270f4a,
title = "2-es t{\'i}pus{\'u} diabetes gondoz{\'a}sa sor{\'a}n felfedezett polymyositis-dermatomyositis",
abstract = "Polymyositis-dermatomyositis is a rare systemic autoimmune disease which belongs to the class of idiopathic inflammatory myopathies. The disease exhibits high inter-individual variability, but chronic myositis is a common feature. As different manifestations often appear in atypical forms, establishing the precise diagnosis can be rather complicated. The prognosis and the patient's life expectations highly depend on whether the clinician considers this possibility in the diagnostic process or not. The authors present the case of a 50-year-old woman who was referred to hospital with suspected myopathy by her general practitioner. The history of the patient, the overall clinical picture and some marked laboratory abnormalities raised the possibility of polymyositis-dermatomyositis, which was unequivocally confirmed by immunological tests. Drug therapy was started immediately with the administration of high dose corticosteroid (1-2 mg/kg/day methylprednisolone), which was found to be an effective strategy leading to fast and remarkable improvement in the patient's condition. From the first hospital day, the patient also received insulin therapy in order to prevent any potential corticosteroid-induced imbalance in her carbohydrate metabolism. The long-term patient management was provided by an interdisciplinary team the members of which (both clinicians and other health care professionals) worked according to a co-ordinated, complex care plan, and managed not only the {"}physiological functions{"} but the different psychological and social problems as well, which are usually associated with the disease. The follow-up period of this polyphase disease process lasted for 4.5 years, during which only two relapses occurred, and muscle strength typically varied between 3 and 4 on a five grade scale with the exception of the relapse periods. Good outcome was attributed to the strict follow-up and individualized therapy/care.",
keywords = "idiopathic inflammatory myopathies, individualized patient management and nursing-care plan, interdisciplinary team",
author = "Francis Samer and M{\'a}ria Cs{\'o}ka and K. Dank{\'o}",
year = "2012",
month = "3",
day = "1",
doi = "10.1556/OH.2012.29300",
language = "Hungarian",
volume = "153",
pages = "467--474",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "12",

}

TY - JOUR

T1 - 2-es típusú diabetes gondozása során felfedezett polymyositis-dermatomyositis

AU - Samer, Francis

AU - Csóka, Mária

AU - Dankó, K.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Polymyositis-dermatomyositis is a rare systemic autoimmune disease which belongs to the class of idiopathic inflammatory myopathies. The disease exhibits high inter-individual variability, but chronic myositis is a common feature. As different manifestations often appear in atypical forms, establishing the precise diagnosis can be rather complicated. The prognosis and the patient's life expectations highly depend on whether the clinician considers this possibility in the diagnostic process or not. The authors present the case of a 50-year-old woman who was referred to hospital with suspected myopathy by her general practitioner. The history of the patient, the overall clinical picture and some marked laboratory abnormalities raised the possibility of polymyositis-dermatomyositis, which was unequivocally confirmed by immunological tests. Drug therapy was started immediately with the administration of high dose corticosteroid (1-2 mg/kg/day methylprednisolone), which was found to be an effective strategy leading to fast and remarkable improvement in the patient's condition. From the first hospital day, the patient also received insulin therapy in order to prevent any potential corticosteroid-induced imbalance in her carbohydrate metabolism. The long-term patient management was provided by an interdisciplinary team the members of which (both clinicians and other health care professionals) worked according to a co-ordinated, complex care plan, and managed not only the "physiological functions" but the different psychological and social problems as well, which are usually associated with the disease. The follow-up period of this polyphase disease process lasted for 4.5 years, during which only two relapses occurred, and muscle strength typically varied between 3 and 4 on a five grade scale with the exception of the relapse periods. Good outcome was attributed to the strict follow-up and individualized therapy/care.

AB - Polymyositis-dermatomyositis is a rare systemic autoimmune disease which belongs to the class of idiopathic inflammatory myopathies. The disease exhibits high inter-individual variability, but chronic myositis is a common feature. As different manifestations often appear in atypical forms, establishing the precise diagnosis can be rather complicated. The prognosis and the patient's life expectations highly depend on whether the clinician considers this possibility in the diagnostic process or not. The authors present the case of a 50-year-old woman who was referred to hospital with suspected myopathy by her general practitioner. The history of the patient, the overall clinical picture and some marked laboratory abnormalities raised the possibility of polymyositis-dermatomyositis, which was unequivocally confirmed by immunological tests. Drug therapy was started immediately with the administration of high dose corticosteroid (1-2 mg/kg/day methylprednisolone), which was found to be an effective strategy leading to fast and remarkable improvement in the patient's condition. From the first hospital day, the patient also received insulin therapy in order to prevent any potential corticosteroid-induced imbalance in her carbohydrate metabolism. The long-term patient management was provided by an interdisciplinary team the members of which (both clinicians and other health care professionals) worked according to a co-ordinated, complex care plan, and managed not only the "physiological functions" but the different psychological and social problems as well, which are usually associated with the disease. The follow-up period of this polyphase disease process lasted for 4.5 years, during which only two relapses occurred, and muscle strength typically varied between 3 and 4 on a five grade scale with the exception of the relapse periods. Good outcome was attributed to the strict follow-up and individualized therapy/care.

KW - idiopathic inflammatory myopathies

KW - individualized patient management and nursing-care plan

KW - interdisciplinary team

UR - http://www.scopus.com/inward/record.url?scp=84858400237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858400237&partnerID=8YFLogxK

U2 - 10.1556/OH.2012.29300

DO - 10.1556/OH.2012.29300

M3 - Article

C2 - 22411220

AN - SCOPUS:84858400237

VL - 153

SP - 467

EP - 474

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 12

ER -